New Heart Disease Drug Can Save More Than 30,000 Lives

New Heart Disease Drug Can Save More Than 30,000 Lives

New heart disease drug can save more than 30,000 lives. This drug has been approved for use in areas of the United Kingdom after a new global trial showed that the drug can lower cholesterol levels by up to 50%.

According to a global trial led by Imperial College London, over 30,000 people could avoid premature death due to heart attacks and strokes.

Approximately half of all adult Australians have a blood cholesterol levels above national guidelines,

Now, a new drug called inclisiran and hailed as “life changing” could prevent 55,000 heart attacks and strokes in the U.K., saving more than 30,000 lives within the next decade.

This drug is administered as an injection. The global trial shows that the drug boosts the liver’s ability to reduce levels of low-density lipoprotein (LDL) cholesterol, known as “bad” cholesterol.

If 300,000 people receive the drug within the next 3 years, a projected 30,000 people could avoid heart attacks and strokes.

According to Prof. Kausik Ray, the director of the Imperial Centre for Cardiovascular Disease Prevention, inclisiran will reduce the heart attack and stroke risk for people with high cholesterol and a history of heart disease from 29% to 20% over the next 10 years.

“The approval of inclisiran is good news for heart patients in the U.K. The twice-yearly injection to lower LDL, or ‘bad,’ cholesterol in patients with existing heart disease, whose cholesterol is not adequately controlled with statins or other drugs, will help to prevent people from having further heart attacks or strokes, ultimately maximizing the numbers of lives saved,” Prof. Sir Nilesh Samani, the medical director of the British Heart Foundation (BHF), said.